Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 13/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL845130 | 0.91 | CYP11B1 (0.43) | CYP11B1CYP11B2ENPP2KDM4ESIRT2 | |
| SCHEMBL5688715 | 0.90 | SIRT2 (0.40) | CYP11B1CYP11B2ENPP2SIRT2 | |
| SCHEMBL2787652 | 0.87 | CYP19A1 (0.36) | CYP11B1CYP11B2 | |
| SCHEMBL2787655 | 0.87 | CYP19A1 (0.36) | CYP11B1CYP11B2 | |
| SCHEMBL21636129 | 0.84 | SIRT2 (0.35) | CYP11B1CYP11B2ENPP2SIRT2 | |
| SCHEMBL7668744 | 0.84 | SIRT2 (0.37) | CYP11B1CYP11B2SIRT2LMNA | |
| SCHEMBL7666687 | 0.84 | GRM5 (0.34) | ENPP2SIRT2ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL1039275 | 0.83 | CYP11B1 (0.41) | CYP11B1CYP11B2ENPP2SIRT2 | |
| SCHEMBL17651947 | 0.81 | SIRT2 (0.36) | CYP11B1CYP11B2ENPP2SIRT2 | |
| SCHEMBL7816830 | 0.81 | SIRT2 (0.35) | CYP11B1CYP11B2ENPP2SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2493862-B1 | IMIDAZOLE DERIVATIVES AS IDO INHIBITORS | NEWLINK GENETICS CORP (US) | 2016-10-05 | — | — | EP | disclosed |
| US-8722720-B2 | Imidazole derivatives as IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722720-B2 | Imidazole derivatives as IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2014-05-13 | — | — | US | disclosed |
| US-20120277217-A1 | Imidazole Derivatives as IDO Inhibitors | NEWLINK GENETICS CORPORATION (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120277217-A1 | Imidazole Derivatives as IDO Inhibitors | NEWLINK GENETICS CORPORATION (US) | 2012-11-01 | — | — | US | disclosed |
| EP-2079706-B1 | METHOD FOR PREPARING MEDETOMIDINE AND ITS SALTS | GRINDEKS JSC (LV) | 2011-07-20 | — | — | EP | disclosed |
| WO-2011056652-A1 | IMIDAZOLE DERIVATIVES AS IDO INHIBITORS | NEWLINK GENETICS (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20050107616-A1 | Alpha-ketoamide derivatives as cathepsin k inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-05-19 | — | — | US | disclosed |
| WO-2003013518-A1 | ALPHA-KETOAMIDE DERIVATIVES AS CATHEPSIN K INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-02-20 | — | — | WO | disclosed |
| US-6143766-A | ENZYME INHIBITORS WITH IMIDAZOLE GROUPS | WARNER-LAMBERT COMPANY (US) | 2000-11-07 | — | — | US | disclosed |
| US-6043254-A | ANTIPROLIFERATIVE AGENT; ENZYME INHIBITOR | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277217-A1 | Imidazole Derivatives as IDO Inhibitors | IDO1, IDO2, INMT | CYP11B1 1011/4885CYP11B2 775/4885ENPP2 930/4885 |
| US-20050107616-A1 | Alpha-ketoamide derivatives as cathepsin k inhibitors | CTSK, CTSE, CTSZ | CYP11B1 2166/4885CYP11B2 2116/4885ENPP2 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.